Viewing Study NCT06086366


Ignite Creation Date: 2025-12-24 @ 4:09 PM
Ignite Modification Date: 2026-01-05 @ 6:24 PM
Study NCT ID: NCT06086366
Status: UNKNOWN
Last Update Posted: 2023-10-17
First Post: 2023-09-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Presynaptic Imaging in Major Depressive Episodes After COVID-19
Sponsor: Centre for Addiction and Mental Health
Organization:

Study Overview

Official Title: Presynaptic Imaging in Major Depressive Episodes After COVID-19
Status: UNKNOWN
Status Verified Date: 2023-10
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PCOV
Brief Summary: The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.
Detailed Description: Participants will undergo two positron emission tomography (PET) scans, one \[11C\]DTBZ scan (for vesicular monoamine transporter 2 (VMAT2) and one \[18F\]SDM8 scan (for synaptic vesicle glycoprotein 2A (SV2A)), as well as one magnetic resonance imaging (MRI) scan.

The main question\[s\] it aims to answer are:

1. The investigators will determine if VMAT2 binding potential (VMAT2 BPND) is reduced in ventral striatum and dorsal putamen in COVID-DNP.
2. The investigators will determine if SV2A total distribution volume (SV2A VT) is reduced in ventral striatum and dorsal putamen in COVID-DNP

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: